Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government to review the current state of non-beta amyloid and non-tau (NANT) targets on underlying Alzheimer's disease (AD) pathophysiology.The totality of scientific and clinical evidence supports the hypothesis that emerging NANT targets play a role in cognitive decline and neurodegeneration in AD. New biomarkers based on NANT targets must be globally developed and implemented with specific consideration of fluid biomarkers as a cost-effective clinical option, to ensure better, more equitable treatment options for AD.
Authors
- Linda J. Van Eldik (ORCID: https://orcid.org/0000-0002-8139-6400)
- Christopher J. Weber
- Emily C. Collins
- Melanie Shulman
- Eric Siemers
- Jin Zhou (ORCID: https://orcid.org/0009-0000-8076-8770)
- David Henley
- Marı́a C. Carrillo
- Peter Johannsen
- M. Gold (ORCID: https://orcid.org/0009-0004-3743-693X)
- Hans Jörg Möbius
Institutions
- Alzheimer's Association (US)
- Biogen (United States) (US)
- University of Kentucky (US)
- Eli Lilly (United States) (US)
- Novo Nordisk (Denmark) (DK)
- Athira Pharma (United States) (US)
- Deerfield (United States) (US)
- Janssen (United States) (US)
- Eisai (United States) (US)
- Acumen Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/trc2.70014
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.33